Temporal variability of QT interval and changes in T wave morphology in dogs as markers of the clinical risk of drug-induced proarrhythmia

Journal of Pharmacological and Toxicological Methods

Volumn 57, Issue 3, 2008, Pages 194-201

  Hanton, G ^a   Yvon, A ^a   Racaud, A ^a  

^a PFIZER INC   (United States)

Author keywords

Arrhythmia; Astemizole; Cisapride; CV5RL ECG lead; Dog; QT interval; QT variability; T wave morphology

Indexed keywords

ASTEMIZOLE; CISAPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART BEAT; HEART HEMODYNAMICS; HEART PROARRHYTHMIA; MALE; NONHUMAN; QT INTERVAL; RISK FACTOR; SINGLE DRUG DOSE; T WAVE;

ADMINISTRATION, ORAL; ANIMALS; ASTEMIZOLE; CISAPRIDE; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL AGENTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; INJECTIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

CANIS FAMILIARIS;

EID: 44649155043     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.03.001     Document Type: Article

References (45)

1. Antzelevitch C. Tpeak-Tend interval as an index of transmural dispersion of repolarization. European Journal of Clinical Investigation 31 (2001) 555-557
2. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Current Opinion in Cardiology 17 (2002) 43-51
3. Atiga W.L., Calkins H., Lawrence J.H., Tomaselli G.F., Smith J.M., and Berger R.D. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. Journal of Cardiovascular Electrophysiology 9 (1998) 899-908
4. Bai R., Lü J., Pu J., Liu N., Zhou Q., Ruan Y., Niu H., Zhang C., Wang L., and Kam R. Left ventricular epicardial activation increases transmural dispersion of repolarization in healthy, long QT and dilated cardiomyopathy dogs. Pacing and Clinical Electrocardiography 28 (2005) 1098-1106
5. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences 24 (2003) 619-625
6. Berger R.D., Kasper E.K., Baughman K.L., Marban E., Calkins H., and Tomaselli G.F. Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 96 (1997) 1557-1565
7. Chezalviel-Guilbert F., Davy J.-M., Poirier J.-M., and Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. Journal of the American College of Cardiology 26 (1995) 787-792
8. Davis A.S. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods. Human and Experimental Toxicology 17 (1998) 677-680
9. De Clerk F., Van de Water A., D'Aubioul J., Lu H.R., Van Rossem K., Hermans A., and Van Ammel K. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundamental and Clinical Pharmacology 16 (2002) 125-140
10. Drolet B., Khalifa M., Daleau P., Hamelin B.A., and Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97 (1998) 204-210
11. Galeano E.J., Yoshida A., Ohnishi Y., Okajima K., Ishida A., Kitamura H., Kubo S., and Yokoyama M. Comparative usefulness of beat-to-beat QT dispersion and QT interval fluctuations for identifying patients with organic heart disease at risk for ventricular arrhythmias. Circulation Journal 67 (2003) 125-128
12. Guth B.D., Germeyer S., Kolb W., and Markert M. Developing a strategy for the non clinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. Journal of Pharmacological and Toxicological Methods 49 (2004) 159-169
13. Hanton G. Preclinical cardiac safety assessment of drugs. Drug in Research and Development 8 (2007) 213-228
14. Hanton G., and Rabemampianina Y. The electrocardiogram of the Beagle dog: Reference values and effect of sex, genetic strain, body position and heart rate. Laboratory Animals 40 (2006) 123-136
15. Hanton G., Bonnet P., Loiret C., and Bazin G. Electrocardiographic effects of high intravenous doses of astemizole in dogs. Toxicology Letters 158 suppl 1 (2005) S53
16. Hanton G., Nahas K., Priou C., Rabemampianina Y., and Baneux P. The QT interval in the dog ECG. Importance in preclinical toxicology and relationship to heart rate. Toxicology Methods 11 (2001) 21-40
17. Haraguchi Y., Yoshinaga M., Sarantuya J., Shimago A., Nishi J., Kono Y., Nomura Y., Kubo R., Eguchi T., Tanaka S., Yanagi S., Fukushige T., Maruyama I., and Kawano Y. Interval representative of transmural dispersion of repolarization in children and young adolescents with congenital long QT syndrome. Circulation Journal 69 (2005) 78-82
18. Hashimoto H., Nishimoto M., Ohmura T., Watanabe S., Ikeda Y., Nakamura R., Umemura K., and Nakashima M. Effects of astemizole on ventricular activation, effective refractory periods, RT intervals, and programmed stimulation-induced ventricular arrhythmias in dog hearts with myocardial infarction. Cardiovascular Pharmacology 31 (1998) 286-291
19. Hoffman P., and Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug induced torsadogenesis. A review or emerging trends. Journal of Pharmacological and Toxicological Methods 53 (2006) 87-105
20. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology 41 (2003) 14-24
21. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
22. Jackman W.M., Friday K.J., Anderson J.L., Aliot E.M., Clark M., and Lazzara R. The long QT syndromes: A critical review, new clinical observations and unifying hypothesis. Progress in Cardiovascular Diseases 31 (1988) 115-172
23. Ks increases short-term QT interval variability and provokes torsades de pointes. British Journal of Pharmacology 151 (2007) 941-951
24. Lubinski A., Kornacewicz-Jach Z., Wnuk-Wojnar A.M., Adamus J., Kempa M., Krolak T., Lewicka-Nowak E., Radomski M., S, and wiatecka G. The terminal portion of the T wave: A new electrocardiographic marker of the risk of ventricular arrhythmias. Pacing and Clinical Electrocardiography 23 (2000) 1957-1959
25. Lupoglazoff J.M., Denjoy I., Berthet M., Neyroud N., Demay L., Richard P., Hainque B., Vaksmann G., Klug D., Leenhardt A., Maillard G., Coumel P., and Guicheney P. Notched T waves on Holter recordings enhance detection of patients with LQT2 (HERG) mutations. Circulation 103 (2001) 1095-1101
26. Moïse N.S., Glimour R.F., and Riccio M.L. An animal model of spontaneous arrhythmic death. Journal of Cardiovascular Electrophysiology 8 (1997) 98-103
27. Moss A., Zareba W., Benhorin J., Locati E., Hall W.J., Robinson J., Schwartz P.J., Towbin J.A., Vincent G.M., Lehman M.H., Keating M.T., MacCluer J.W., and Timothy K.W. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 92 (1995) 2929-2934
28. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
29. 1 receptor antagonist astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Research 76 (1995) 110-119
30. Schneider J., Hauser R., Andreas J.-O., Linz K., and Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. European Journal of Pharmacology 512 (2005) 53-60
31. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
32. Shimizu W., and Antzelevitch C. Cellular basis for the ECG features of LQT1 form of the long QT syndrome. Effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsades de pointes. Circulation 98 (1998) 2314-2322
33. Shimizu W., and Antzelevitch C. Cellular basis for long QT, transmural dispersion of repolarization and Torsade de Pointes in the long QT syndrome. Journal of Electrocardiology 32 (1999) 177-184 (suppl)
34. Thomsen M.B., Oros A., Schoenmakers M., van Opstal J.M., Mass J.N., Beekman J.D.M., and Vos M.A. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarization. Cardiovascular Research 73 (2007) 521-530
35. Thomsen M.B., Truin M., van Opstal J.M., Beekman J.D.M., Volders P.G.A., Stengl M., and Vos M.A. Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Research in Cardiology 100 (2005) 279-287
36. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D.M., de Pater G., van Opstal J., Volders P.G.A., and Vos M.A. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453-2459
37. Van der Linde H., Van de Water A., Loots W., Van Deuren B., Lu H.R., Van Ammel K., Peeters M., and Gallacher D.J. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs. Journal of Pharmacological and Toxicological Methods 52 (2005) 168-177
38. Webster R., Allan G., Anto-Awuakye K., Harrison A., Kidd T., Leishman D., Phipps J., and Walker D. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dogs. Xenobiotica 31 (2001) 633-650
39. Weissenburger J., Davy J.-M., Chezalviel F., Ertzbischoff O., Poirier J.M., Engel F., Lainée P., Penin E., Motte G., and Cheymol G. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. Journal of Pharmacological and Experimental Therapeutics 259 (1991) 871-883
40. Weissenburger J., Nesterensko V.V., and Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. Journal of Cardiovascular Electrophysiology 11 (2000) 290-304
41. Wysowsky D.K., Corken A., Gallo-Torres H., Talarico L., and Rodriguez E.M. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. American Journal of Gastroenterology 96 (2001) 1698-1703
42. Yamamoto K., Tamura T., Imai R., and Yamamoto M. Acute canine model for drug-induced torsades de pointes in drug safety evaluation. Influence of anesthesia and validation with quinidine and astemizole. Toxicological Sciences 60 (2001) 165-176
43. Yan G.-X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
44. Zabel M., and Malik M. Practical use of T wave morphology assessment. Cardiac Electrophysiology Review 6 (2002) 316-322
45. Zabel M., Hohnloser S.H., Be, hrens S., Li Y.-G., Woosley R.L., and Franz M.R. Electrophysiologic features of torsades de pointes: Insights from a new isolated rabbit heart model. Journal of Cardiovascular Electrophysiology 8 (1997) 1148-1158